Publications
Print   |  A  |  A
Publications

Jefford M, Mileshkin L, Matthews J, Raunow H, et al. Satisfaction with the decision to participate in cancer clinical trials is high, but understanding is a problem. Support Care Cancer. 2010 Feb 23. [Epub ahead of print]

Cher L, Rosenthal MA, Drummond K et al. The use of chemotherapy in patients with gliomas: patterns of care in Victoria from 1998-2000. Journal of Clinical Neuroscience 2008; 15: 398-401.

Rosenthal MA, Ashley D, Drummond K. Brain stem gliomas: patterns of care in Victoria from 1998-2000. Journal of Clinical Neuroscience 2008; 15: 237-240.

Rosenthal MA et al. Intramedullary spinal cord tumours: patters of care in Victoria 1998-2000. Asia pacific Journal of Clinical Oncology. 2008; 4: 77-80.

Carden C and Rosenthal MA. A nomogram to predict the development of a nomogram. British Journal of Urology. 2008; 102: 402.

Craig P Carden CP, Larkin J and Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro-Oncology 2008; 10: 624-630

Rosenthal MA. Chemotherapy in the elderly patient with prostate cancer: no need to be nervous. Editorial in European Urology 2008; Aug 8.

Roberts-Thomson R, Rosenthal MA, Gonzales M, Drummond K. Brain Metastasis in Hormone Refractory Prostate Cancer: A Changing Natural History? Internal Medicine Journal (in press)

Tie J, Gunawardana DH, Rosenthal MA. 201Tl SPECT in high-grade gliomas: Differentiation of tumor recurrence from radiation necrosis. Journal of Clinical Neuroscience 2008; 15: 1327-1334

Price T, Lipton L, Rosenthal MA et al. Safety and Pharmacokinetics of Motesanib in Combination With Gemcitabine for the Treatment of Patients With Solid Tumours. British Journal of Cancer 2008; 99:1387-94

Mark J. McKeage, Joachim Von Pawel, Michael B. Jameson, Mark A. Rosenthal et al. Randomized Phase Ib/II Study of 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA/ASA404) Combined with Carboplatin and Paclitaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer. British Journal of Cancer. 2008; 16: 2006-12.

Pavlick AC, Wu J, Roberts J, Rosenthal MA et al. Phase I Study of Bryostatin 1, a Protein Kinase C Modulator, Preceding Cisplatin in Patients with Refractory Non-hematologic Tumors. Cancer Chemother Pharmacol. 2009 Feb 17.

Pezaro C, Rosenthal MA, Gurney H. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer (CRPC). American Journal of Clinical Oncology 2009; 32: 338-341.

Dally M, Rosenthal M, Drummond K, et al. Radiotherapy management of patients diagnosed with glioma in Victoria (1998-2000). J Medical Imagining and Radiation Oncology 2009; 53: 318-324.

Mark J. McKeage, Joachim Von Pawel, Michael B. Jameson, Mark A. Rosenthal et al. Phase II Study of ASA404 (5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) 1800mg/m2 Combined with Carboplatin and Paclitaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer. Lung Cancer (in press)

Tran B, Rosenthal MA. Survival Comparison between Glioblastoma Multiforme and other Incurable Cancers. Journal of Clinical Neuroscience (in press)

Hui K. Gan, Mark A. Rosenthal, Anthony Dowling, Renate Kalnins, Elizabeth Algar, Angela Benson, Anne-Marie Woods, Lawrence Cher. A Phase II trial of primary temozolomide in patients with Grade III oligodendroglial brain tumors Neuro-Oncology (in press)

Dresemann G, Weller M, Rosenthal MA, Hoffken K et al. Imatinib plus hydroxyurea versus hydroxyurea monotherapy in progressive glioblastoma (GBM) – an International open label Randomised Phase III study (Ambrosia Study). Journal of Neuro-Oncology (In press)

Broad, A, Campano, LM, Davis, ID, Rosenthal, M and Toner, G A phase II trial of anti-idiotypic p53 peptides (Pentrys) in patients with hormone-refractory prostate cancer. Asia Pacific Journal of Clinical Oncology 3: 1-8.. 1-8: (2007)

Barlow, J., Cebon, J., Davis, I.D., Frederiksen, K.S., Lundsgaard, D., McArthur, G.A., Moller, N.P.H., Nicholaou, T., Skak, K., Skrumsager, B.K. and Thygesen, P. Recombinant human interleukin-21 (rIL-21): an open-label, two arm, phase 1 trial in patients with metastatic melanoma. Clinical Cancer Research. In press.: (2007)

Baka, S., Beith, J., Davis, I., Harris, P., Haydon, A., Hersey, P., Kefford, R., Margison, G.P., McArthur, G.A., Middleton, M.R., Mortimer, P., Ranson, M., Sabharwal, A., Seebaran, A., Thompson, D. and Watson, A.J. A randomised trial of the combination of lomeguatrib and temozolomide and temozolomide alone in patients with advanced melanoma. Journal of Clinical Oncology. In press.: (2007)

Lim, E. and Rosenthal, M.A. Diagnosing cancer: changing patterns of care. Internal Medicine Journal. 37: 124-6 (2007)

Grigg, A.P., Ritchie, D.S., Roberts, A.W., Seymour, J.F., et. al. The hyper-CVAD-rituximab chemotherapy program followed by high-dose busulphan, melphalan and autologous stem cell transplantation produces excellent event free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol. In press.: (2006)

Grigg, A.P. The effect of hydroxyurea on sperm count, motility and morphology in adult males with sickle cell or myeloproliferative disease. Int Med J. In press.: (2006)

D'Souza, A.B., Ebeling, P.R., Grigg, A.P. and Szer, J. Zoledronic acid prevents bone loss after allogeneic hemopoietic stem cell transplantation. Int Med J. 36: 600-3 (2006)

Grigg, A.P. and Hughes, T. The role of allogeneic stem cell transplantation for adult chronic myeloid leukaemia in the imatinib era. Biol Blood Marrow Transplant. 12: 795-807 (2006)

Bardy, P., Diviney, M., Grigg, A.P., Murphy, N., Szer, J., et. al. Donor methylenetetrahydrofolate reductase genotype is associated with graft versus host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant. 37: 773-779 (2006)

Ganju, V. and Grigg, A.P. PET positive progressive transformation of germinal centres masquerading as relapsed Hodgkin lymphoma post autograft. Leukaemia and Lymphoma. 47: 764-65 (2006)

Back to Top